drugset / Trial / NCT03891615

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

NCT03891615

NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a combination of drugs as a possible treatment for EGFR-Mutated Advanced Lung Cancer. The names of the study drugs involved in this study are Niraparib and Osimertinib.

Timeline

Start
2019-06-06
Primary completion
2022-04-30
Completion
2024-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Niraparib Small molecule Oral
Subject Osimertinib Small molecule Oral

Indications